- Home
- Articles
- latamerica
- prostate treatment
Prostate Treatment Articles & Analysis
12 articles found
Flotufolastat F 18 binds to prostate-specific membrane antigen (PSMA) (IC50= 4.4 nM) expressed on cells, including prostate cancer cells. In patients with recurrent prostate cancer who require local treatment, positron emission tomography (PET) with an 18F-labeled ligand provides accurate diagnostic imaging. The 18F group in ...
Recently, in the renowned academic journal Nature Medicine, the Kimmel Cancer Center at Johns Hopkins University published Phase 2 clinical results regarding enoblituzumab, a monoclonal antibody targeting B7-H3, for the treatment of prostate cancer. The results demonstrate that enoblituzumab can successfully induce the body's anti-cancer activity, showing ...
For example, a TPD drug developed by Arvinas has achieved proof-of-concept in clinical trials for the treatment of breast and prostate cancer. Researchers are also developing TPD drugs to treat other types of diseases. ...
Currently, ADC has played a significant role in the treatment of some malignant tumors, such as trastuzumab in the treatment of breast cancer, but its application in the treatment of prostate cancer (PCa) progress slowly. In recent years, ADC has made rapid progress in the treatment of metastatic ...
While Movember is not just about prostate cancer, it is a great place to start; prostate cancer is the second most common cancer among men worldwide1, and the second leading cause of cancer death in American men.2 In the UK, more than 52,000 men are diagnosed with prostate cancer every year on average – which is 143 men every day, according ...
Background Since Walsh and Donker first introduced the anatomic nerve-sparing technique for retropubic radical prostatectomy1 (RRP) in the treatment of clinically localized prostate cancer, the importance of minimizing damage to the neurovascular bundle (NVB) has been recognized as a critical element for the preservation of potency and urinary continence ...
Introduction: Several prostatic stents were developed in the last three decades, none of which were able to provide a real alternative in patients unfit or unwilling to undergo classical prostatic surgeries. In this study, we report the results of the use of a newly developed prostatic stent—the Allium™ Triangular ...
The ClarityDX Prostate® test provides patients and physicians with an accurate prediction of clinically significant prostate cancer to support decision-making and improve health outcomes for men suspected of having prostate cancer. ...
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. ...
” Recently, Nanostics announced positive results from the clinical validation study of its lead prostate cancer diagnostic test, ClarityDX Prostate®, showing 94% sensitivity, 37% specificity, 49% positive predictive value, and 90% negative predictive value for predicting clinically significant (grade group ≥2) prostate cancer. ...
For urologists and prostate cancer patients, early detection and treatment are critical to successful outcomes. ...
The study is also greatly benefiting from further expansion into the US with the addition of a new patient recruitment site at an award-winning United States clinical research institution ("Partner"). ClarityDX Prostate is a novel liquid biopsy test for the early diagnosis of clinically significant prostate cancer. ...